World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
33398
World Ranking
11684
National Ranking
5990

Harold E. Bays publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Harold E. Bays sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 405 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Harold E. Bays D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Harold E. Bays sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Harold E. Bays is affiliated with the Louisville Metabolic and Atherosclerosis Research Center in the United States. Their research contributions span multiple areas within medicine, with a focus on surgery, endocrinology, diabetes and metabolism, pharmacology, physiology, and cardiology and cardiovascular medicine.

Their work primarily addresses topics including pharmacology and obesity treatment, diet and metabolism studies, lipoproteins and cardiovascular health, diabetes treatment and management, obesity and health practices, diabetes, cardiovascular risks and lipoproteins, and bariatric surgery and outcomes.

Harold E. Bays has contributed to several peer-reviewed journals, frequently publishing in venues such as Obesity Pillars with 45 publications, Journal of Clinical Lipidology with 10, American Journal of Preventive Cardiology with 6, Journal of the American College of Cardiology with 6, and Obesity with 4.

Their recent significant papers include:

  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity, 2021, JAMA
  • Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients, 2023, New England Journal of Medicine
  • Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity, 2023, JAMA
  • Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation, 2022, European Journal of Preventive Cardiology
  • Ten things to know about ten cardiovascular disease risk factors, 2021, American Journal of Preventive Cardiology

Frequent co-authors collaborating with Harold E. Bays include:

  • Kausik K. Ray
  • Angela Fitch
  • Alberico L. Catapano
  • Christie M. Ballantyne
  • Maciej Banach

Overall, Harold E. Bays maintains a comprehensive research portfolio centered on the intersection of metabolic disorders, cardiovascular health, and therapeutic interventions related to obesity, diabetes, and lipid management. Their publications reflect multidisciplinary approaches that combine clinical investigation with pharmacological and physiological studies.

Best Publications

  • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

    Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

    Steven R. Smith;Neil J. Weissman;Christen M. Anderson;Matilde Sanchez

  • National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

    Terry A. Jacobson;Matthew K. Ito;Kevin C. Maki;Carl E. Orringer

  • Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

    Claude Gagné;Harold E Bays;Stuart R Weiss;Pedro Mata

  • National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

    Terry A. Jacobson;Kevin C. Maki;Carl E. Orringer;Peter H. Jones

  • Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

    Harold E Bays;J Michael González-Campoy;George A Bray;Abbas E Kitabchi

  • Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

    Kausik K. Ray;Harold E. Bays;Alberico L. Catapano;Narendra D. Lalwani

  • National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

    Terry A. Jacobson;Matthew K. Ito;Kevin C. Maki;Carl E. Orringer

  • The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys

    H. E. Bays;R. H. Chapman;S. Grandy

  • Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

    Michael H Davidson;Evan A Stein;Harold E Bays;Kevin C Maki

  • Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

    Harold E. Bays;Peter P. Toth;Penny M. Kris-Etherton;Nicola Abate

  • Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

    R.H. Knopp;H. Gitter;T. Truitt;H. Bays

  • Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

    Michael J. Koren;Pernille Lundqvist;Michael Bolognese;Joel M. Neutel

  • Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

    Harold E. Bays;Christie M. Ballantyne;John J. Kastelein;Jonathan L. Isaacsohn

  • Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.

    Priscilla Hollander;Alok K. Gupta;Raymond Plodkowski;Frank Greenway

  • Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)

    Christie M. Ballantyne;Harold E. Bays;John J. Kastelein;Evan Stein

  • Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

    Harold E Bays;Paul B Moore;Margaret A Drehobl;Sidney Rosenblatt

  • Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

    Frederick J. Raal;Robert P. Giugliano;Marc S. Sabatine;Michael J. Koren

  • Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

    Harold E Bays;Ann P Tighe;Richard Sadovsky;Michael H Davidson

Frequent Co-Authors

Christie M. Ballantyne
Christie M. Ballantyne Baylor College of Medicine
Evan A. Stein
Evan A. Stein Medpace (United States)
Michael H. Davidson
Michael H. Davidson University of Chicago
Peter Jones
Peter Jones University of Cambridge
Kausik K. Ray
Kausik K. Ray Imperial College London
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Alberico L. Catapano
Alberico L. Catapano University of Milan
Lawrence A. Leiter
Lawrence A. Leiter University of Toronto
Maciej Banach
Maciej Banach John Paul II Catholic University of Lublin
Terry A. Jacobson
Terry A. Jacobson Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond a traditional MD program, there are numerous flexible options available online. Those looking for administrative or support roles can explore the best online medical billing and coding schools, which offer accredited programs with financial aid opportunities.

If nursing is your passion but you’re concerned about tough admissions processes, consider the nursing school no entrance exam options. These programs remove barriers like the TEAS or HESI exams, making it easier to start your nursing education.

Aspiring healthcare leaders should look into online health administration programs for an accelerated path to management positions in hospitals and clinics. For practicing nurses, the asn to np bridge programs offer a streamlined way to advance from an associate’s degree to becoming a nurse practitioner.

Whatever your background, these diverse online pathways help you enter or advance in the healthcare field while balancing work, life, and study.

Best Scientists Citing Harold E. Bays

Trending Scientists

Recently Published Articles